IXICO PLC (AIM:IXI, OTC:PHYOF) says Dr Lynne Hughes, an international neurology clinical trial research expert, will join the company as a senior therapeutic advisor.
The medical imaging advanced analytics company said Dr Hughes will use her 35 years of experience in the global clinical research field to advise and support the management of the company.
Dr Hughes will specifically focus on “determining adjacent therapeutic areas into which IXICO can diversify into and expand the deployment of its proprietary neuroimaging CRO and AI data analytics services”.
Chief executive Giulio Cerroni said: “The appointment of Dr Hughes brings significant additional experience and understanding to enable IXICO to further strengthen and scale our capabilities as the trusted neuroimaging partner of choice to the global pharmaceutical industry.”
During her 23-year tenure at US healthcare data science giant IQVIA, Hughes held the position of vice president and global head of medical strategy, where she was responsible for overseeing 450 trials, including 125 trials relating to Alzheimer’s, more than 75 trials on Parkinson’s and 65 on Multiple Sclerosis.
She sits on multiple neurology therapeutic focused advisory boards, as well as co-chairing one of the three global taskforces of the G20/World Economic Forum Alzheimer's Collaboration, is a senior advisor to the Global Alzheimer's Platform foundation and is a member of the NIA/NIH taskforce for recruitment into AD trials and the development of the US National Framework.
In addition, Dr Hughes has worked with various research organisations including the Gates Foundation, Alzheimer's Association, Alzheimer's Research UK, ADI and is a member of the G7 and G20 World Dementia Councils.